Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Transitional Cell 16 Urinary Bladder Neoplasms 15 Carcinoma, Merkel Cell 10 Neoplasm Metastasis 8 Carcinoma, Renal Cell 8 Breast Neoplasms 8 Neoplasms 6 Triple Negative Breast Neoplasms 5 Melanoma 5 Ureteral Neoplasms 4 Stomach Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 4 Ovarian Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Uterine Cervical Neoplasms 3 Urethral Neoplasms 3 Skin Neoplasms 3 Prostatic Neoplasms 3 Colorectal Neoplasms 3 Small Cell Lung Carcinoma 2 Sarcoma 2 Neuroendocrine Tumors 2 Head and Neck Neoplasms 2 Endometrial Neoplasms 2 Carcinoma, Squamous Cell 2 Carcinoma, Hepatocellular 2 Uveal Melanoma 1 Urothelial Cancer 1 Turcot syndrome 1 Thymoma 1

Interventions

enfortumab vedotin 2 zimberelimab 1 sacituzumab govitecan 1 pembrolizumab 1 avelumab 1 Gemcitabine 1 Cisplatin 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Metastatic Urothelial Cancer × avelumab × 1 year × Clear all

NCT03547973 2026-03-16

TROPHY U-01

Gilead Sciences

Phase 2 Recruiting

827 enrolled 1 FDA

Metastatic Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡